RU2393221C2 - Аденовирус с обращенной генной экспрессией и его применение - Google Patents

Аденовирус с обращенной генной экспрессией и его применение Download PDF

Info

Publication number
RU2393221C2
RU2393221C2 RU2005114516/13A RU2005114516A RU2393221C2 RU 2393221 C2 RU2393221 C2 RU 2393221C2 RU 2005114516/13 A RU2005114516/13 A RU 2005114516/13A RU 2005114516 A RU2005114516 A RU 2005114516A RU 2393221 C2 RU2393221 C2 RU 2393221C2
Authority
RU
Russia
Prior art keywords
protein
adenovirus
promoter
nucleic acid
cells
Prior art date
Application number
RU2005114516/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2005114516A (ru
Inventor
Пер Сонне ХОЛЬМ (DE)
Пер Сонне ХОЛЬМ
Original Assignee
Пер Сонне ХОЛЬМ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/005583 external-priority patent/WO2003099859A2/de
Application filed by Пер Сонне ХОЛЬМ filed Critical Пер Сонне ХОЛЬМ
Publication of RU2005114516A publication Critical patent/RU2005114516A/ru
Application granted granted Critical
Publication of RU2393221C2 publication Critical patent/RU2393221C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2005114516/13A 2002-10-15 2003-10-15 Аденовирус с обращенной генной экспрессией и его применение RU2393221C2 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE10248039.7 2002-10-15
DE10248039 2002-10-15
DE10322530 2003-05-19
DE10322530.7 2003-05-19
DE10324085.3 2003-05-27
EPPCT/EP03/05583 2003-05-27
DE10324085 2003-05-27
PCT/EP2003/005583 WO2003099859A2 (de) 2002-05-27 2003-05-27 Neue verwendung von adenoviren und dafür codierenden nukleinsäuren

Publications (2)

Publication Number Publication Date
RU2005114516A RU2005114516A (ru) 2006-01-20
RU2393221C2 true RU2393221C2 (ru) 2010-06-27

Family

ID=34317534

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005114516/13A RU2393221C2 (ru) 2002-10-15 2003-10-15 Аденовирус с обращенной генной экспрессией и его применение

Country Status (5)

Country Link
JP (1) JP4988199B2 (ko)
KR (1) KR101123510B1 (ko)
AU (1) AU2003271730A1 (ko)
CA (1) CA2515650C (ko)
RU (1) RU2393221C2 (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561050C2 (ru) * 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
RU2685876C2 (ru) * 2013-09-24 2019-04-23 Юниверсити Оф Вашингтон Сру Итс Сентер Фор Коммершиализэйшн Белки, связывающие десмоглеин 2 (dsg2), и их применение
RU2768287C1 (ru) * 2018-07-10 2022-03-23 Генемедицине Ко., Лтд. Противоопухолевая композиция

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
EP1689446B1 (de) * 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
CA2610360A1 (en) * 2004-12-31 2006-07-06 Per Sonne Holm E1-minus adenoviruses and use thereof
JP5584393B2 (ja) * 2004-12-31 2014-09-03 ホルム，ペル・ゾンネ 動物細胞における多剤耐性を逆転させる方法
HUE064471T2 (hu) * 2018-03-05 2024-03-28 Klinikum Rechts Der Isar Der Technischen Univ Muenchen Daganatok kezelése onkolitikus adenovírus és CDK4/6 inhibitor kombinációjával

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU682854B2 (en) * 1993-02-16 1997-10-23 Onyx Pharmaceuticals Cytopathic viruses for therapy and prophylaxis of neoplasia
US6254862B1 (en) * 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
ES2287181T3 (es) * 2000-12-28 2007-12-16 Per Sonne Holm Sistemas adenovirales y sus aplicaciones.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WONG H.K. et al. "Complementary functions of E1a conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters", J Virol. 1994 Aug; 68(8): 4910-4920. GANLY I. et al., "Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis". Gene Ther. 2001 Mar; 8(5): 369-375. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561050C2 (ru) * 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
RU2685876C2 (ru) * 2013-09-24 2019-04-23 Юниверсити Оф Вашингтон Сру Итс Сентер Фор Коммершиализэйшн Белки, связывающие десмоглеин 2 (dsg2), и их применение
RU2768287C1 (ru) * 2018-07-10 2022-03-23 Генемедицине Ко., Лтд. Противоопухолевая композиция

Also Published As

Publication number Publication date
JP2006518589A (ja) 2006-08-17
AU2003271730A2 (en) 2004-05-04
CA2515650C (en) 2019-10-01
CA2515650A1 (en) 2004-04-29
KR101123510B1 (ko) 2012-04-12
AU2003271730A1 (en) 2004-05-04
RU2005114516A (ru) 2006-01-20
JP4988199B2 (ja) 2012-08-01
KR20050061530A (ko) 2005-06-22

Similar Documents

Publication Publication Date Title
US11268073B2 (en) Use of adenovirus and nucleic acids coding therefor
JP5618896B2 (ja) 新規アデノウイルス、それをコードする核酸及びその使用
JP5873893B2 (ja) アデノウイルスおよびそれをコードしている核酸の新たな使用
US20170252443A1 (en) Methods for reversing multiple resistance in animal cells
AU2010257327B2 (en) Adenovirus expressing genes in reverse order and use thereof
RU2393221C2 (ru) Аденовирус с обращенной генной экспрессией и его применение
AU2015201828B2 (en) Novel use of adenoviruses and nucleic acids coding therefor